300 related articles for article (PubMed ID: 33081804)
1. Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition.
Sachpazidis I; Mavroidis P; Zamboglou C; Klein CM; Grosu AL; Baltas D
Radiat Oncol; 2020 Oct; 15(1):242. PubMed ID: 33081804
[TBL] [Abstract][Full Text] [Related]
2. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
3. Predicting Biochemical Failure in Irradiated Patients With Prostate Cancer by Tumour Volume Measured by Multiparametric MRI.
Oerther B; Buren MV; Klein CM; Kirste S; Nicolay NH; Sprave T; Spohn S; Gunashekar DD; Hagele L; Bielak L; Bock M; Grosu AL; Bamberg F; Benndorf M; Zamboglou C
In Vivo; 2020; 34(6):3473-3481. PubMed ID: 33144456
[TBL] [Abstract][Full Text] [Related]
4. [
Bettermann AS; Zamboglou C; Kiefer S; Jilg CA; Spohn S; Kranz-Rudolph J; Fassbender TF; Bronsert P; Nicolay NH; Gratzke C; Bock M; Ruf J; Benndorf M; Grosu AL
Radiother Oncol; 2019 Dec; 141():214-219. PubMed ID: 31431366
[TBL] [Abstract][Full Text] [Related]
5. Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.
Spohn SKB; Sachpazidis I; Wiehle R; Thomann B; Sigle A; Bronsert P; Ruf J; Benndorf M; Nicolay NH; Sprave T; Grosu AL; Baltas D; Zamboglou C
Front Oncol; 2021; 11():652678. PubMed ID: 34055621
[TBL] [Abstract][Full Text] [Related]
6. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
Royce TJ; Mavroidis P; Wang K; Falchook AD; Sheets NC; Fuller DB; Collins SP; El Naqa I; Song DY; Ding GX; Nahum AE; Jackson A; Grimm J; Yorke E; Chen RC
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):227-236. PubMed ID: 32900561
[TBL] [Abstract][Full Text] [Related]
7. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
[TBL] [Abstract][Full Text] [Related]
8. Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI.
Her EJ; Haworth A; Reynolds HM; Sun Y; Kennedy A; Panettieri V; Bangert M; Williams S; Ebert MA
Radiat Oncol; 2020 Jul; 15(1):172. PubMed ID: 32660504
[TBL] [Abstract][Full Text] [Related]
9. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
11. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data.
Levegrün S; Jackson A; Zelefsky MJ; Skwarchuk MW; Venkatraman ES; Schlegel W; Fuks Z; Leibel SA; Ling CC
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1064-80. PubMed ID: 11704332
[TBL] [Abstract][Full Text] [Related]
12. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
13. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.
Riches SF; Payne GS; Desouza NM; Dearnaley D; Morgan VA; Morgan SC; Partridge M
Br J Radiol; 2014 May; 87(1037):20130813. PubMed ID: 24601648
[TBL] [Abstract][Full Text] [Related]
14. Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer.
Duque-Santana V; Diaz-Gavela A; Recio M; Guerrero LL; Peña M; Sanchez S; López-Campos F; Thuissard IJ; Andreu C; Sanz-Rosa D; Achard V; Gómez-Iturriaga A; Molina Y; Del Cerro Peñalver E; Couñago F
World J Urol; 2023 Dec; 41(12):3829-3838. PubMed ID: 37966505
[TBL] [Abstract][Full Text] [Related]
15. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
[TBL] [Abstract][Full Text] [Related]
16. Inverse and forward optimization of one- and two-dimensional intensity-modulated radiation therapy-based treatment of concave-shaped planning target volumes: the case of prostate cancer.
Corletto D; Iori M; Paiusco M; Brait L; Broggi S; Ceresoli G; Iotti C; Calandrino R; Fiorino C
Radiother Oncol; 2003 Feb; 66(2):185-95. PubMed ID: 12648791
[TBL] [Abstract][Full Text] [Related]
17. Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland.
Ghobadi G; de Jong J; Hollmann BG; van Triest B; van der Poel HG; Vens C; van der Heide UA
Radiother Oncol; 2016 Apr; 119(1):97-103. PubMed ID: 26897517
[TBL] [Abstract][Full Text] [Related]
18. Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer.
Thomann B; Sachpazidis I; Koubar K; Zamboglou C; Mavroidis P; Wiehle R; Grosu AL; Baltas D
Radiother Oncol; 2018 Apr; 127(1):62-67. PubMed ID: 29548559
[TBL] [Abstract][Full Text] [Related]
19. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
[TBL] [Abstract][Full Text] [Related]
20. A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps.
Casares-Magaz O; van der Heide UA; Rørvik J; Steenbergen P; Muren LP
Radiother Oncol; 2016 Apr; 119(1):111-6. PubMed ID: 26987473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
